Edition:
United States

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

1.29USD
22 Sep 2017
Change (% chg)

-- (--)
Prev Close
$1.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,526
52-wk High
$2.85
52-wk Low
$0.76

Chart for

About

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's... (more)

Overall

Beta: 2.39
Market Cap(Mil.): $72.45
Shares Outstanding(Mil.): 56.16
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 60.89 15.95
EPS (TTM): -- -- --
ROI: -- 0.19 15.19
ROE: -- 2.32 13.87

BRIEF-Vermillion reports Q2 loss per share $0.04

* Q2 revenue rose 27 percent to $898,000 Source text for Eikon: Further company coverage:

Aug 09 2017

BRIEF-Vermillion Q1 loss per share $0.05

* Q1 revenue $726,000 versus $505,000 Source text for Eikon: Further company coverage:

May 11 2017

BRIEF-Vermillion files for resale of up to 6.6 mln shares of common stock

* Files for resale of up to 6.6 million shares of co's common stock - sec filing Source text - http://bit.ly/2oVnfQO Further company coverage:

Apr 11 2017

BRIEF-Vermillion enters into a contract with TriCare South

* Aspira labs announces tricare south contract Source text for Eikon: Further company coverage:

Mar 30 2017

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $52.51 +1.08
Becton Dickinson and Co (BDX.N) $193.06 +1.50
Arrayit Corp (ARYC.PK) $0.01 +0.00

Earnings vs. Estimates